Lead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent.

IF 0.4 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Indian Journal of Nuclear Medicine Pub Date : 2024-03-01 Epub Date: 2024-05-29 DOI:10.4103/ijnm.ijnm_2_23
Parul Thakral, Ishita Barat Sen, Subha Shankar Das, Michael K Schultz, Jyotsna Kumari, C B Virupakshappa, Dharmender Malik
{"title":"Lead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent.","authors":"Parul Thakral, Ishita Barat Sen, Subha Shankar Das, Michael K Schultz, Jyotsna Kumari, C B Virupakshappa, Dharmender Malik","doi":"10.4103/ijnm.ijnm_2_23","DOIUrl":null,"url":null,"abstract":"<p><p>Targeted alpha therapy (TAT) using lead-212 (Pb-212)-labeled peptides presents an attractive option for the treatment of metastatic neuroendocrine tumors (NETs). As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-α-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-α-NET with Ga-68 DOTANOC.</p>","PeriodicalId":45830,"journal":{"name":"Indian Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232724/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijnm.ijnm_2_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Targeted alpha therapy (TAT) using lead-212 (Pb-212)-labeled peptides presents an attractive option for the treatment of metastatic neuroendocrine tumors (NETs). As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-α-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-α-NET with Ga-68 DOTANOC.

铅-203 VMT-α-神经内分泌肿瘤闪烁成像:一种前景广阔的治疗药物。
使用铅-212(Pb-212)标记的肽进行靶向α治疗(TAT)是治疗转移性神经内分泌肿瘤(NET)的一个极具吸引力的选择。由于 Pb-203 是 Pb-212 的精确诊断替代物,因此用 Pb-203 标记肽进行成像是评估用 Pb-212 标记制剂进行 TAT 可行性的重要前提。在此,我们展示了一位转移性NET患者使用Pb-203 VMT-α-NET(一种体生长抑素受体靶向药物)的成像数据,并展示了Pb-203 VMT-α-NET与Ga-68 DOTANOC的匹配分布。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Indian Journal of Nuclear Medicine
Indian Journal of Nuclear Medicine RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
CiteScore
0.70
自引率
0.00%
发文量
46
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信